ITMCTR2000003235尚未招募未知
A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia
Wuhan Hospital Of Traditional Chinese and Western Medicine (Wuhan 1st Hospital)0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 70（—）
- 性别
- All
入选标准
- •1. Meet the convalescence of COVID-19 diagnostic criteria;
- •2. Short breath, hyperhidrosis, dry cough, chest distress, palpitation and other clinical discomfort symptoms of lung and heart function decline, in which 3 symptoms appear at the same time, or the visual analogue score of single symptom (VAS) >=4 points;
- •3. Patients who were discharged for more than 2 weeks were cured;
- •4. Aged 18-70 years old;
- •5. Sign informed consent.
排除标准
- •1. Because of other reasons, such as shortness of breath, hyperhidrosis, dry cough, chest distress, palpitation, etc;
- •2. Patients with difficulty in taking drugs orally due to basic diseases;
- •3. There are serious basic diseases that affect survival, including uncontrolled clinically significant heart, lung, kidney, digestion, blood disease, neuropsychiatric disease, immune disease, metabolic disease, malignant tumor, severe malnutrition, etc;
- •4. Allergic constitution, allergic to drugs involved in the treatment plan;
- •5. Pregnant or lactating women;
- •6. Those who can't cooperate in mental state, suffer from mental disease, have no self-control and can't express clearly;
- •7. Those who are participating in other clinical trials;
- •8. According to the judgment of the researchers, there will be patients with complicated enrollment or poor compliance that affect the efficacy and safety evaluation.
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the efficacy, safety, and pharmacokinetics (PK) of enzastaurin for the prevention of arterial events in patients with vEDS confirmed with COL3A1 mutationsvascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mutationsMedDRA version: 20.0Level: PTClassification code 10014316Term: Ehlers-Danlos syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-006574-23-NLAytu BioPharma, Inc.260
进行中（未招募）
1 期
A clinical study to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent, after surgical treatment and/or Chronic Thromboembolic Pulmonary Hypertension (CTEPH).Chronic Thromboembolic Pulmonary Hypertension, inoperable or persistent/recurrentMedDRA version: 21.1Level: LLTClassification code 10068739Term: Chronic thromboembolic pulmonary hypertensionSystem Organ Class: 100000004855EUCTR2018-002823-41-ATActelion Pharmaceuticals Ltd280
进行中（未招募）
1 期
EVOLVE-FD: Effects of EVOLocumab VErsus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids in patients with Familial DysbetalipoproteinemiaFamilial DysbetalipoproteinemiaEUCTR2018-003476-12-NLniversity Medical Center Utrecht30
进行中（未招募）
1 期
Efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failureAcute heart failureEUCTR2013-001498-25-ATovartis Pharma Services AG6,800
进行中（未招募）
1 期
QGE031 Phase 2b dose-finding study to investigate efficacy and safety in adolescents with CSChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2017-004207-52-EEovartis Pharma AG48